

Best Practices to Facilitate Innovation: Medical Professional Societies

Dr. Allen S. Lichter
American Society of Clinical Oncology

Maintaining Public Trust

1. Council of Medical Specialty Societies (CMSS) Code of Conduct
2. Disclosure for our members



Council of Medical Specialty Societies

CODE FOR INTERACTIONS WITH COMPANIES

| | |
|--|----|
| IV. Principles for Interaction | 9 |
| 1. Independence | 9 |
| 2. Transparency..... | 11 |
| 3. Accepting Charitable Contributions..... | 13 |
| 4. Accepting Corporate Sponsorships..... | 13 |
| 5. Society Meetings..... | 15 |
| 6. Awarding of Research Grants | 19 |
| 7. Clinical Practice Guidelines..... | 19 |
| 8. Society Journals..... | 23 |
| 9. Standards for Advertising | 24 |
| 10. Standards for Licensing | 25 |

Posting 100% of our Support

Non-profit support:

| | | |
|--|---|----------------|
| The Breast Cancer Research Foundation | 2013 - Young Investigator Award | \$120,000.00 |
| The Breast Cancer Research Foundation | 2013 - Long-term International Fellowship (LIFE) | \$130,000.00 |
| The Breast Cancer Research Foundation | Evelyn H. Lauder Young Investigator Award Endowment Fund | \$1,300,000.00 |
| The Cholangiocarcinoma Foundation | 2013 - Young Investigator Award | \$60,000.00 |
| The Community Foundation for Greater New Haven | General Mission Support | \$1,000.00 |
| Community Foundation Greater Des Moines | Cancer Research | \$250.00 |
| The Don Shula Foundation | 2012 - Young Investigator Award | \$57,937.14 |
| Doris Duke Charitable Foundation | 2012-2013 Medical Student Rotation for Underrepresented Populations | \$40,000.00 |

Healthcare companies:

| | | |
|----------------------|--|--------------|
| sanofi-aventis U.S. | 2013 - Gastrointestinal Cancers Symposium | \$100,000.00 |
| Seattle Genetics | 2012 - Young Investigator Award | \$60,000.00 |
| Seattle Genetics | 2012 - Annual Meeting Patient Advocate Scholarship Program | \$10,000.00 |
| Seattle Genetics | 2012 - Hematologic Cancer Portal | \$28,000.00 |
| Seattle Genetics | 2012 - Annual Meeting Internet Stations | \$56,000.00 |
| Seattle Genetics | 2012 - ASCO iMeetings Mobile App | \$11,200.00 |
| Sinplicity | In-Kind Donation | \$400.00 |
| Symphogen A/S | 2012 - Young Investigator Award | \$5,000.00 |
| Teva Pharmaceuticals | 2012 - Young Investigator Award | \$20,000.00 |

ASCO's Policy on Disclosure of Relationships with Companies

JOURNAL OF CLINICAL ONCOLOGY

ASCO SPECIAL ARTICLE

American Society of Clinical Oncology: Policy for Relationships With Companies

American Society of Clinical Oncology

Processed as a Rapid Communication manuscript. See accompanying article

doi: 10.1200/JCO.2013.49.4997

From the American Society of Clinical Oncology, Alexandria, VA.

Published online ahead of print at www.jco.org on April 22, 2013.

Author's disclosures of potential con-

I. INTRODUCTION

The American Society of Clinical Oncology ("the Society") is dedicated to conquering cancer through

Code") is a set of principles that requires signatory societies to adopt policies for transparency and independence in transactions and activities involving for-profit entities that develop, produce, market, or distribute drugs, biologics, medical devices, medical



Disclosure Management System

Manage your disclosures across ASCO

[Home](#) ➔ [Disclosure](#)

ASCO Form for Disclosure of Relationships with Companies

The purpose of this system is to provide ASCO audiences with information about certain relationships that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. The form should be updated when there is new information or at the time of any new ASCO activity. Review the detailed [instructions](#) prior to completing the form.

[Continue](#)

1. Board membership

[Update](#)

| Company | Recipient | Comments | Start Date | End Date |
|------------------------------|-----------|----------|------------|----------|
| No Relationships to Disclose | | | | |

2. Employment

[Update](#)

| Company | Recipient | Comments | Start Date | End Date |
|------------------------------|-----------|----------|------------|----------|
| No Relationships to Disclose | | | | |

3. Stock/stock options

[Update](#)

| Company | Recipient | Comments | Start Date | End Date |
|------------------------------|-----------|----------|------------|----------|
| No Relationships to Disclose | | | | |

Can a Uniform System be Created?

Toward a Harmonized and Centralized Conflict of Interest Disclosure

Progress From an IOM Initiative

Allen S. Lichter, MD

Ross McKinney, MD

health care providers, and physicians and re
should convene a broad-based . . . process to c
standard content, a standard format, and stand
dures for disclosure of financial relationships w

Summary

- Medical professional societies have been active in creating transparent and trustworthy processes designed to maintain public trust.
- Disclosure of relationships and management of conflicts have been a key objective.
- Having a uniform disclosure system would be an important step forward.